Contact Information
  •   11190 Sunrise Valley Dr., Suite 300, Reston, VA, 20191
  •   stp@toxpath.org
  •   703-438-7508
open

STP Virtual Continuing Education Course

Home / Meetings / Annual Meetings / STP Virtual Continuing Education Courses
STP Virtual Continuing Education Courses
AAVSB RACE Approved for CE Credits logo seal

Antibody Drug Conjugates (ADCs) as Cancer Therapies

Recordered Friday, September 11, 2020

Co-Chairs: William O. Iverson, DVM, Consultant; and Nancy E. Everds, DVM, DACVP, Seattle Genetics

Antibody-drug conjugates (ADCs), which use a specific antibody to deliver a toxic payload to target cells, hold great promise to increase efficacy and reduce adverse side effects, especially for oncology drugs. Six ADC molecules have received marketing approval in the US over the past 18 years. Nonclinical safety assessment has proven challenging as many ADCs still have steep dose-response curves and low therapeutic indices. Toxicities in many different organs and tissues have been seen, including bone marrow, skin, liver, kidney, eye, gastrointestinal tract, and nervous system. ADC-related toxicities may be more challenging to predict and manage than those seen with small molecules or unconjugated antibodies. This has led to more sophisticated engineering of antibodies, linkers, and drugs to increase internalization of drug by target cells, decrease off-target toxicity, and decrease bystander effects. This course will give an overview of synthesis and mechanisms of representative ADCs, and the clinical and anatomic pathology findings associated with different classes of agents, including immunomodulatory molecules and PROTACS.

Course Speakers

William O. Iverson
Introduction
William O. Iverson,
DVM, Consultant

Shyra J. Gardai
Immune Modulatory Activity of Traditional and Nontraditional ADCs
Shyra J. Gardai,
PhD, Seattle Genetics

Lakshmaiah Gingipalli
Recent Progress in Antibody Drug Conjugates and PROTACs as New Modalities: Application to Oncology Drug Discovery
Lakshmaiah Gingipalli,
PhD, AstraZeneca

Niraj K. Tripathi
Clinical Pathology Effects of Antibody Drug Conjugates in Toxicology Studies
Niraj K. Tripathi,
BVSc, MVSc, PhD, DACVP,
Covance

Bindu Bennet
Anatomic Pathology Associated with Antibody Drug Conjugates
Matthew D. Smith,
DVM, PhD, DACVP, Charles River Laboratories

  •  11190 Sunrise Valley Drive,
    Suite 300, Reston, VA 20191